Skip to search formSkip to main contentSkip to account menu

CG0070

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL
INTRODUCTION AND OBJECTIVES: CG0070 is a selective oncolytic adenovirus that exploits retinoblastoma (Rb) pathway defects. We… 
2018
2018
LBA24 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 12 MONTH INTERIM RESULTS FROM A MULTICENTER PHASE II TRIAL
2017
2017
INTERIM RESULTS FROM A SINGLE‐ARM MULTICENTER PHASE II TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG‐UNRESPONSIVE NON‐MUSCLE‐INVASIVE BLADDER CANCER (NMIBC): PNFLBA‐13
2016
2016
MP13-19 A PHASE II/III TRIAL OF CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-REFRACTORY NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)
2012
2012
Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure.
271 Background: Loss of retinoblastoma (Rb) tumor suppressor activity occurs commonly in bladder cancer and leads to upregulation… 
2012
2012
Updated results of a phase I/II trial of intravesical CG0070 in patients with superficial bladder cancer after BCG failure.
271 Background: Loss of retinoblastoma (Rb) tumor suppressor activity occurs commonly in bladder cancer and leads to upregulation… 
2012
2012
Activity of intravesical CG0070 in Rb-inactive superficial bladder cancer after BCG failure: Updated results of a phase I/II trial.
4593 Background: Loss of retinoblastoma (Rb) tumor suppressor activity occurs commonly in bladder cancer and leads to… 
2010
2010
Use of a bioamplification assay to detect nonselective recombinants and assess the genetic stability of oncolytic adenoviruses.
Detection of nonselective adenoviruses in tissue- or tumor-selective oncolytic adenovirus preparations presents a technical… 
2006
2006
844: A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma (TCC) of the Bladder after Bacillus Calmette-Guerin (BCG) Failure
2005
2005
CG0070, a conditionally replicating GM-CSF armed oncolytic adenovirus for the treatment of bladder cancer
5019 In spite of early intervention with Bacillus Calmette-Guerin (BCG) and transurethral resection (TUR), high recurrence rates… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)